0001832511-25-000013
SEC filingP3 Health Partners' Q2 2025 results reflect a 6% revenue decline driven by an 11% reduction in at-risk members from strategic contract terminations, partially offset by improved premium deficiency reserve benefits.
P3 Health Partners Inc. reported a net loss of $43.7 million for the three months ended June 30, 2025, compared to a net loss of $28.8 million in the prior year period. Total operating revenue decreased 6% to $355.8 million, driven by a $22.6 million decline in capitated revenue. This was primarily attributed to an 11% reduction in at-risk members, from 128,100 at June 30, 2024, to 114,100 at June 30, 2025, resulting from the strategic termination of underperforming payor contracts and affiliate providers.
Gross profit fell sharply to $4.4 million from $14.0 million in Q2 2024, as the decline in revenue was partially offset by a 4% decrease in medical claims expense. The medical expense ratio remained high, with total medical expense (including other medical expense) consuming nearly all of total operating revenue. The operating loss widened to $34.1 million from $31.3 million, as a $3.3 million reduction in corporate, general and administrative expenses—driven by headcount reductions and the sale of Florida operations—was offset by a higher premium deficiency reserve benefit and other factors.
The company operates a single reportable segment focused on population health management for Medicare Advantage members. Capitated revenue, representing 99% of total operating revenue, is the core economic driver. The strategic pruning of the member base, while reducing top-line scale, is intended to improve the quality of the remaining contract portfolio. The 11% member decline was the primary factor in the revenue decrease, though the company notes that per-member revenue can be influenced by risk adjustment factor (RAF) scores and quality incentives.
Other patient service revenue, a minor component at 1% of total revenue, also declined 16% to $4.1 million. The company's non-GAAP metric, medical margin, decreased to $30.6 million from $41.1 million, reflecting the pressure on the core capitated arrangement's profitability.
Management's outlook is dominated by a going concern warning. The company explicitly states that existing cash resources are not sufficient to support planned operations for at least the next year, raising substantial doubt about its ability to continue. To address this, P3 is actively exploring additional capital through debt and equity financing, having recently secured up to $70.0 million in unsecured promissory notes from VGS 5, with $15.0 million drawn as of June 30, 2025, and an additional $15.0 million drawn in July/August 2025.
Strategically, the company intends to continue its periodic review of provider and payor contracts, which may lead to further exits from underperforming relationships. The focus remains on managing medical costs, which represent 90% of total operating expenses, and achieving operating efficiencies as the platform matures. The company expects platform support costs to decrease as a percentage of revenue over time, though absolute corporate expenses may rise to support public company operations and growth investments.
As of June 30, 2025, P3 Health Partners Inc. reported unrestricted cash and cash equivalents of $38.6 million, a slight decrease from $38.8 million at December 31, 2024. The Company has a significant working capital deficit of $348.5 million, driven by current liabilities of $505.0 million against current assets of $156.5 million. Total stockholders' equity fell to $44.5 million from $75.9 million at year-end 2024, primarily due to a net loss of $87.9 million for the six months ended June 30, 2025. The accumulated deficit reached $544.0 million. Note 2 explicitly states that substantial doubt exists about the Company's ability to continue as a going concern within one year after the financial statement issuance date, citing recurring losses and adverse claims experience. The Company is exploring additional debt and equity financing but notes no assurance such financing will be available on acceptable terms.
The Notes section does not contain a dedicated commitments or contractual obligations table with specific purchase commitments. The primary obligations disclosed relate to debt instruments. Gross long-term debt totaled $215.3 million as of June 30, 2025, with a current portion of $80.0 million. This includes a $65.0 million Term Loan Facility due December 2025, a $15.0 million Repurchase Promissory Note due June 2026, and several related-party promissory notes (VGS 1-5) with interest rates ranging from 13.5% to 19.5% maturing between 2027 and 2028. The VGS 5 Promissory Note provides for up to $70.0 million in total funding, with $16.1 million drawn as of June 30, 2025, and an additional $15.0 million tranche funded in July and August 2025. These notes contain mandatory prepayment provisions upon asset sales or change of control.
No share buybacks or dividends were disclosed. Debt financing was the primary capital activity. During the six months ended June 30, 2025, the Company received $45.0 million in proceeds from long-term debt, net of original issue discount, primarily from the VGS 4 and VGS 5 Promissory Notes. Debt issuance costs and original issue discounts totaled $23.9 million for these new notes, including $22.3 million related to the fair value of warrants issued to lenders. Repayments of short-term and long-term debt were $0.7 million. The Company also issued Class A common stock warrants valued at $22.3 million in connection with the new debt. No capital expenditures were disclosed in the Notes section.
Note 11 confirms the Company operates under one reportable segment. Total operating revenue for the six months ended June 30, 2025 was $729.0 million, a 5.0% decline from $767.6 million in the prior year period. Capitated revenue comprised 98.9% of total revenue. Customer concentration is significant: five health plan customers each accounted for 10% or more of total revenue, collectively comprising 75% of total revenue for the six months ended June 30, 2025. No geographic mix is disclosed at the segment level.
For the six months ended June 30, 2025, P3 Health Partners Inc. reported a net loss of $87.9 million, which was the primary driver of the $50.1 million in cash used in operating activities. The gap between net loss and operating cash flow was significantly narrowed by non-cash adjustments, most notably $42.1 million in depreciation and amortization and a $12.9 million premium deficiency reserve. However, a $5.3 million mark-to-market gain on stock warrants partially offset these adjustments.
Working capital changes consumed a net $10.0 million in cash. A significant source of cash was a $27.8 million decrease in health plan receivables, but this was more than offset by uses including a $14.5 million increase in other long-term assets, a $13.7 million decrease in health plan settlements payable, and a $10.6 million increase in accrued interest. The minimal $0.9 million increase in claims payable is a stark contrast to the $55.8 million increase in the prior year period, indicating a significant tightening of the company's claims payment cycle or lower medical cost accruals, which contributed to the year-over-year deterioration in operating cash flow.
The company's investing activities were negligible, with only $50,000 in proceeds from an asset sale and no reported capital expenditures. Financing activities provided a critical lifeline, generating $45.3 million in net cash, almost entirely from $45.0 million in new long-term debt. This debt issuance was essential to fund the operating shortfall. The company did not repurchase shares or pay dividends. The overall cash position decreased by $4.8 million during the period, ending at $39.3 million, underscoring the company's reliance on external financing to sustain operations as noted in its going concern disclosure.